130 related articles for article (PubMed ID: 38349267)
1. 2-Thioxo-3,4-dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR
El-Gaby MSA; Abdel Reheim MAM; Akrim ZSM; Naguib BH; Saleh NM; El-Adasy ABAAM; El-Adl K; Mohamady S
Drug Dev Res; 2024 Feb; 85(1):e22143. PubMed ID: 38349267
[TBL] [Abstract][Full Text] [Related]
2. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
4. Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR
Anwer KE; El-Hddad SSA; Abd El-Sattar NEA; El-Morsy A; Khedr F; Mohamady S; Keshek DE; Salama SA; El-Adl K; Hanafy NS
RSC Adv; 2023 Nov; 13(50):35321-35338. PubMed ID: 38053688
[TBL] [Abstract][Full Text] [Related]
5. Iodoquinazoline-derived VEGFR-2 and EGFR
Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
9. New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity.
Ghorab MM; Soliman AM; El-Adl K; Hanafy NS
Bioorg Chem; 2023 Nov; 140():106791. PubMed ID: 37611529
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
El-Adl K; Abdel-Rahman AA; Omar AM; Alswah M; Saleh NM
Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100237. PubMed ID: 34862655
[TBL] [Abstract][Full Text] [Related]
11. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis,
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
RSC Adv; 2022 Apr; 12(20):12913-12931. PubMed ID: 35496328
[TBL] [Abstract][Full Text] [Related]
14. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
Fadaly WAA; Nemr MTM; Kahk NM
Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, docking, ADMET and anticancer evaluations of
Alsulaimany M; El-Adl K; Aljohani AKB; Alharbi HY; Alatawi OM; Aljohani MS; El-Morsy A; Almadani SA; Alsimaree AA; Salama SA; Keshek DE; Mohamed AA
RSC Adv; 2023 Dec; 13(51):36301-36321. PubMed ID: 38093733
[TBL] [Abstract][Full Text] [Related]
19. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
[TBL] [Abstract][Full Text] [Related]
20. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]